Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma

Keyphrases

• Hepatocellular Carcinoma 100%
• Neoadjuvant 100%
• Hepatocellular Cancer 100%
• Preoperative Setting 66%
• Tumor 33%
• Oncological Outcomes 33%
• Kinase Inhibitor 33%
• Immune Response 33%
• High Probability 33%
• Targeted Therapy 33%
• Treatment Modalities 33%
• T Cell Response 33%
• Surgical Outcomes 33%
• Neoadjuvant Setting 33%
• Locally Advanced Disease 33%
• Positive Impact 33%
• Postoperative Period 33%
• Pathological Response 33%
• Tumor Immunity 33%
• Disease Burden 33%
• Immune Checkpoint Inhibitor Therapy 33%
• Downstaging 33%
• Optimal Integration 33%
• Immune Checkpoint Inhibitor Combinations 33%
• Perioperative Therapy 33%
• Neoadjuvant Immunotherapy 33%
• Micrometastatic Disease 33%
• Recurrence Probability 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Liver Cell Carcinoma 100%
• Immunotherapy 100%
• Neoplasm 66%
• Recurrent Disease 66%
• Immune Checkpoint Inhibitor 66%
• Diseases 66%
• Phosphotransferase Inhibitor 33%

Medicine and Dentistry

• Neoadjuvant Immunotherapy 33%